Literature DB >> 16782564

Intra-lesional injections of collagenase are ineffective in the treatment of keloid and hypertrophic scars.

Norbert Kang1, Branavan Sivakumar, Roy Sanders, Charles Nduka, David Gault.   

Abstract

The treatment of keloid and hypertrophic scars remains difficult. Enzymatic digestion of keloid scars has been previously proposed as an effective treatment strategy for reducing the volume of keloid scars. To test this, we administered intra-lesional injections of pure collagenase (between 600 and 4500 units for each scar) into the keloid and hypertrophic scars of seven human volunteers (five keloid and two hypertrophic scars). Five patients (three keloid and two hypertrophic) received more than one injection of collagenase. The treatment resulted in a temporary reduction in scar volume for three of the patients with keloid scars. However, scar volumes for these three patients returned to the same (or greater) levels after 6 months of follow-up. Treatment with collagenase produced no change in scar volume for the two patients with hypertrophic scar. Side effects were numerous and severe including; pain, swelling, blistering, ulceration and ecchymosis at the site of injection. One patient required admission to hospital for 48 h after the first injection. Maximum length of follow-up was 6 months. None of the seven patients completed the study and returned for final follow-up at 2 years. This pilot study suggests that treatment of keloid and hypertrophic scars with intra-lesional injections of collagenase is ineffective.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782564     DOI: 10.1016/j.bjps.2005.11.022

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  4 in total

Review 1.  Managing keloid scars: From radiation therapy to actual and potential drug deliveries.

Authors:  Chenyu Huang; Longwei Liu; Zhifeng You; Yanan Du; Rei Ogawa
Journal:  Int Wound J       Date:  2019-03-12       Impact factor: 3.315

2.  The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.

Authors:  Alexis Thomas; Ardeshir Bayat
Journal:  Ther Clin Risk Manag       Date:  2010-11-04       Impact factor: 2.423

Review 3.  A Review of Current Keloid Management: Mainstay Monotherapies and Emerging Approaches.

Authors:  Emily E Limmer; Donald A Glass
Journal:  Dermatol Ther (Heidelb)       Date:  2020-07-23

4.  Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes.

Authors:  Aurelia Trisliana Perdanasari; Matteo Torresetti; Luca Grassetti; Fabio Nicoli; Yi Xin Zhang; Talal Dashti; Giovanni Di Benedetto; Davide Lazzeri
Journal:  Burns Trauma       Date:  2015-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.